3-MESITYL-4-(4-METHOXYBENZOYL)-1-OXASPIRO[4.4]NON-3-EN-2-ONE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ZKVINIRLQSAJFP-UHFFFAOYSA-N
Smiles	COc1ccc(cc1)C(=O)C2=C(C(=O)OC23CCCC3)c4c(C)cc(C)cc4C
InChI	InChI=1S/C25H26O4/c1-15-13-16(2)20(17(3)14-15)21-22(25(29-24(21)27)11-5-6-12-25)23(26)18-7-9-19(28-4)10-8-18/h7-10,13-14H,5-6,11-12H2,1-4H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C25H26O4
Molecular Weight	390.47
AlogP	5.93
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	52.6
Molecular species	None
Aromatic Rings	2.0
Heavy Atoms	29.0

Assay Description	Organism	Bioactivity
Acaricidal activity against adult Tetranychus cinnabarinus (carmine spider mite) assessed as mortality at 6.25 mg/L after 72 hr by immersion method	Tetranychus cinnabarinus	55.2 %
Insecticidal activity against third-instar nymph of Aphis fabae (black bean aphids) assessed as mortality after 72 hr by spray method	Aphis fabae	21.0 ug.mL-1
Insecticidal activity against third-instar larvae of Mythimna separata (Oriental armyworm) assessed as mortality after 72 hr by spray method	Mythimna separata	26.0 ug.mL-1
Acaricidal activity against adult Tetranychus cinnabarinus (carmine spider mite) assessed as mortality after 72 hr by immersion method	Tetranychus cinnabarinus	1.0 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2287723
PubChem	76320178

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).